Biologic Drugs Challenge the Biopharma Industry

Oct 05, 2018
By Pharmaceutical Technology Editors

Advances in biologic drug development require increased methodological and technological innovation from the biopharma industry. In an interview with Mark Emalfarb, CEO of Dyadic International, a biotechnology company focused on developing biologic vaccines and biologic drugs, and Mario DiPaola, PhD, senior scientific director at contract research organization Charles River Laboratories, Pharmaceutical Technology explored how to create better biologic building blocks to help minimize the pressure placed on the industry by current development cost and time-to-market challenges (1).

Issues such as these and other biomanufacturing challenges will be addressed at bioLive, being held adjacent to CPhI Worldwide 2018 in Madrid, Spain, from Oct. 9–11, 2018. Relevant events include a keynote by Dr Tae Han Kim, CEO, Samsung Biologics, exploring ‘Global Growth in Biomanufacturing’ on Wednesday, Oct. 10, 2018, 10:30–11:00am; an interview with Dawn Ecker, consultant and bioTRAK database manager, BioProcess Technology Consultants, on Wednesday, Oct. 10, 2018, 11:00–11:30am; and panel discussion on ‘Growth Perspectives in the US and Europe’ featuring Ecker and Paul Thorning, CEO, Crystec Pharma.

Learn more at bioLIVE, an exhibition and conference for biopharmaceutical development and manufacturing which is launching this year adjacent to CPhI Worldwide. bioLIVE is a new specialized event focusing on large-molecule biopharma and, more specifically, on manufacturing and processing within the industry.

Reference

1. F. Mirasol, Pharmaceutical Technology, 42 (8) 2018.

native1_300x100
lorem ipsum